Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
Taiho Pharmaceutical and development partner Cullinan Therapeutics said on April 28 that the US FDA has accepted for review their new drug application for zipalertinib, an EGFR tyrosine kinase inhibitor.The filing seeks approval for zipalertinib to treat patients with locally…
To read the full story
Related Article
- Taiho’s Zipalertinib Hits Primary Goal in 1st Line NSCLC Trial
August 17, 2026
- Taiho Begins Rolling US NDA Submission for Zipalertinib
November 26, 2025
BUSINESS
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
- Shionogi to Get US$36.9 Million as US Govt Procures Fetroja
August 31, 2026
- Daiichi’s CD25-Directed ADC DS1025 Enters Clinic
August 31, 2026
- Bayer Files Kerendia in Japan for Broader CKD Use
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…